利妥昔单抗治疗寻常型天疱疮有效并具有减少激素用量的作用
该研究为Ritux 3试验的事后分析,纳入中重度寻常型天疱疮患者,比较利妥昔单抗联合短程泼尼松与单用泼尼松的疗效与安全性。结果显示联合治疗组24个月时无激素完全缓解率更高(90% vs 28%),累积泼尼松剂量更低,严重激素相关不良事件更少。
要点
- 利妥昔单抗联合短程泼尼松较单用泼尼松显著提高无激素完全缓解率。
- 联合治疗组3/4级激素相关不良事件发生率为34%,低于单用组的67%。
核心结论
- 在中重度寻常型天疱疮患者中,利妥昔单抗联合短程泼尼松比单用泼尼松更有效。
- 利妥昔单抗治疗患者激素暴露更少,发生严重或危及生命的激素相关不良事件的可能性更低。
研究设计与样本
- 法国研究者发起的III期开放标签随机对照试验(Ritux 3)的独立事后分析。
- 主要终点为第24个月时无激素完全缓解(CRoff)持续≥2个月。
主要发现
- 第24个月时,利妥昔单抗联合泼尼松组38例中34例(90%)达到CRoff≥2个月,单用泼尼松组36例中10例(28%)。
- 单用泼尼松组36例中8例(22%)因不良事件退出治疗;利妥昔单抗联合泼尼松组1例因妊娠退出。
- 单用泼尼松组36例中24例(67%)发生3/4级激素相关不良事件,利妥昔单抗联合泼尼松组38例中13例(34%)。
临床怎么用
- 对于中重度寻常型天疱疮,可考虑利妥昔单抗联合短程泼尼松方案以快速诱导缓解并减少激素累积剂量。
- 该方案有助于降低严重激素相关不良事件风险,但需注意利妥昔单抗相关不良反应及妊娠等特殊情况。
局限性
- 本研究为事后分析,非预设主要分析,可能存在选择偏倚。
- 开放标签设计可能影响不良事件报告等主观终点评估。
- 样本量有限,仅纳入中重度患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. OBJECTIVES: To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV. METHODS: This was an independently conducted post hoc analysis of the moderate-to-severe PV subset enrolled in the Ritux 3 study. Patients were randomized to rituximab plus 0·5 or 1·0 mg kg-1 per day prednisone tapered over 3 or 6 months, or 1·0 or 1·5 mg kg-1 per day prednisone alone tapered over 12 or 18 months, respectively (according to disease severity). The primary end point was complete remission at month 24 without CS (CRoff) for ≥ 2 months, and 24-month efficacy and safety results were also reported. RESULTS: At month 24, 34 of 38 patients (90%) on rituximab plus prednisone achieved CRoff ≥ 2 months vs. 10 of 36 patients (28%) on prednisone alone. Median total cumulative prednisone dose was 5800 mg in the rituximab plus prednisone arm vs. 20 520 mg for prednisone alone. Eight of 36 patients (22%) who received prednisone alone withdrew from treatment owing to AEs; one rituximab-plus-prednisone patient withdrew due to pregnancy. Overall, 24 of 36 patients (67%) on prednisone alone experienced a grade 3/4 CS-related AE vs. 13 of 38 patients (34%) on rituximab plus prednisone. CONCLUSIONS: In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs. What's already known about this topic? Pemphigus vulgaris (PV) is the most common type of pemphigus. Corticosteroids, a standard first-line treatment for PV, have significant side-effects. Although their effects are unproven, adjuvant corticosteroid-sparing agents are routinely used to minimize steroid exposure and corticosteroid-related side-effects. There is evidence that the anti-CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add? This study provides a more detailed analysis of patients with PV enrolled in an investigator-initiated trial. Rituximab plus prednisone had a steroid-sparing effect and more patients achieved complete remission off prednisone. Fewer patients experienced grade 3 or grade 4 steroid-related adverse events than those on prednisone alone. This collaboration between academia and industry, utilizing independent post hoc analyses, led to regulatory authority approvals of rituximab in moderate-to-severe PV.
引用
- Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2019. PMID: 31487383. doi:10.1111/bjd.18482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。